In the last 30 years remarkable progress has been made in developing treatments that have helped transform HIV into a manageable chronic condition for many people around the world. While we don’t yet have a cure, those who have access to modern HIV treatments can now live long and full lives thanks to investment in research, treatments and public health initiatives.
This World AIDS Day, UNAIDS released a new report reflecting on this incredible progress but it also highlights the great inequalities regarding access to treatments and infection rates around the world.
Today, two-thirds of all new infections and deaths occur on the continent of Africa and in sub-Saharan Africa girls and women are particularly vulnerable to infection. In addition, there are rising levels of infection in East Asia and Latin America among at-risk populations.
Access to treatment is also an area where we see imbalances both between developed and developing nations but also within some of the world’s wealthiest countries. UNAIDS estimates that 13 million people still do not have access to the antiretroviral therapies (ART).
The report argues that while science has been at the core of the battle against the disease – discovering and developing treatments, prophylactics, and diagnostics other factors have hampered the potential of these weapons. These factors include:
At Cromos Pharma we celebrate the great achievements made to date and the valuable lessons learned in the battle against HIV which have helped inform our current approach to beating COVID-19. Yet we know HIV/AIDS is still a threat and are proud to play a role in supporting our clients in their clinical research focused on better medicines, prophylactic treatments, generics to help increase accessibility to treatments and we hope one day a cure.
Cromos Pharma is pleased to share news about our latest project - an international double-blind placebo-controlled clinical trial of RPH-104 in acute ST-Elevation Myocardial Infarction (STEMI). The trial involving patients in the US and in Russia will investigate how a biologic RPH-104 developed by R-Pharm can reduce an acute inflammatory response after myocardial infarction and lead to improved outcomes for STEMI patients.
Throughout March we have been highlighting colorectal cancer, the amazing teams of researchers who are continuously fighting this disease, as well as the millions of patients and families who have been deeply affected by this silent killer. To close out this month of awareness-raising we want to introduce you to a real-life hero and colon cancer survivor - Arlene.
March is Colorectal Cancer Awareness Month. Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide according to 2020 figures from the Global Cancer Observatory.
Ukraine, the eight largest European country by population, is an attractive location for sponsors conducting clinical research for a number of key reasons. Cromos Pharma has been successfully managing clinical trials in Ukraine since 2006. This article looks at just some of the benefits of locating your next study here.
Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute.
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.